Matches in Wikidata for { <http://www.wikidata.org/entity/Q91392717> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q91392717 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q91392717 description "scientific article published on 01 March 2020" @default.
- Q91392717 description "wetenschappelijk artikel" @default.
- Q91392717 description "наукова стаття, опублікована 1 березня 2020" @default.
- Q91392717 name "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 name "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 type Item @default.
- Q91392717 label "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 label "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 prefLabel "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 prefLabel "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Yea" @default.
- Q91392717 P1433 Q91392717-B9CE1A5A-6FA8-4EAC-A385-032CE44E4F95 @default.
- Q91392717 P1476 Q91392717-9450AC78-2A15-4F7B-992B-8C285E9D3449 @default.
- Q91392717 P2093 Q91392717-0534CB12-B203-4D66-B3A9-AAE78C6D3C43 @default.
- Q91392717 P2093 Q91392717-1D6DCE45-6CDA-4FF9-9CEF-CE1F9C1F0973 @default.
- Q91392717 P2093 Q91392717-3CAD4420-90EC-48BB-889D-719B26011B34 @default.
- Q91392717 P2093 Q91392717-4ACC43C3-AABA-46C2-93BD-E71B7C251564 @default.
- Q91392717 P2093 Q91392717-626666A3-80BE-49BD-A761-1709EC30AEE2 @default.
- Q91392717 P2093 Q91392717-698F3FAA-82DE-44E8-89ED-991BE7B9C69C @default.
- Q91392717 P2093 Q91392717-73BC4549-B896-4D70-B574-FC9BF6A12093 @default.
- Q91392717 P2093 Q91392717-96CA58F4-3CF1-4C08-A0B0-824CCFC00556 @default.
- Q91392717 P2093 Q91392717-B3686ED9-145C-41D8-B1A9-227CE21E3C91 @default.
- Q91392717 P2093 Q91392717-C648A9A7-5751-4839-B4D2-DD2593B41C6C @default.
- Q91392717 P2093 Q91392717-C79D0BEA-CAF9-45CC-9CFE-A895B31C133D @default.
- Q91392717 P2093 Q91392717-E21F02DD-6274-48A5-AED4-8A6DDFF92D09 @default.
- Q91392717 P2093 Q91392717-EF5DDCCF-D47B-421D-802A-67AF6B7FA3D9 @default.
- Q91392717 P2093 Q91392717-F63E7921-9351-4814-B39A-3DC6EE2F0671 @default.
- Q91392717 P2093 Q91392717-F8EBF95D-7CBE-4DD3-B826-AC7C0CE8F3E9 @default.
- Q91392717 P2860 Q91392717-8B563BED-8239-477D-B8BE-6F0200D6437C @default.
- Q91392717 P304 Q91392717-B432C4D2-7651-425D-9103-8D675832DAD3 @default.
- Q91392717 P31 Q91392717-BEB5684A-153D-4BE6-82AF-9DABC48E9F62 @default.
- Q91392717 P356 Q91392717-2DEDC5AA-EB98-45FC-9EB5-89897796D8B4 @default.
- Q91392717 P433 Q91392717-90AD180C-B4D1-4FE2-BD58-893A9AB3316A @default.
- Q91392717 P478 Q91392717-41B79599-F46E-4405-A80F-8168541B1C35 @default.
- Q91392717 P577 Q91392717-2129836D-8CE2-43DD-ACFB-5EDD782C0A9E @default.
- Q91392717 P698 Q91392717-7B5DA164-14F8-468B-BF78-8DA516DDA05D @default.
- Q91392717 P921 Q91392717-0E2F734E-AF36-4A65-B364-802F6ED757CD @default.
- Q91392717 P921 Q91392717-90ECBD99-96C0-4739-81E2-7893DC6F1D97 @default.
- Q91392717 P921 Q91392717-A3E679BB-42ED-4EB4-8A85-72527601EDF2 @default.
- Q91392717 P921 Q91392717-F61EE354-4CC2-4B21-A67F-85F1DD1A50D8 @default.
- Q91392717 P356 JIZ592 @default.
- Q91392717 P698 31755526 @default.
- Q91392717 P1433 Q4051141 @default.
- Q91392717 P1476 "The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States" @default.
- Q91392717 P2093 "Aaron Glass" @default.
- Q91392717 P2093 "Brian Cuzzo" @default.
- Q91392717 P2093 "Dongliang Wang" @default.
- Q91392717 P2093 "Heather Friberg" @default.
- Q91392717 P2093 "Jeffrey R Currier" @default.
- Q91392717 P2093 "Mark Abbott" @default.
- Q91392717 P2093 "Mark Polhemus" @default.
- Q91392717 P2093 "Matthew Bonaparte" @default.
- Q91392717 P2093 "Michael F Princiotta" @default.
- Q91392717 P2093 "Rafael De La Barra" @default.
- Q91392717 P2093 "Richard G Jarman" @default.
- Q91392717 P2093 "Saranya Sridhar" @default.
- Q91392717 P2093 "Stephen J Thomas" @default.
- Q91392717 P2093 "Tifany Machabert" @default.
- Q91392717 P2093 "Timothy P Endy" @default.
- Q91392717 P2860 Q24628768 @default.
- Q91392717 P304 "1057-1069" @default.
- Q91392717 P31 Q13442814 @default.
- Q91392717 P356 "10.1093/INFDIS/JIZ592" @default.
- Q91392717 P433 "7" @default.
- Q91392717 P478 "221" @default.
- Q91392717 P577 "2020-03-01T00:00:00Z" @default.
- Q91392717 P698 "31755526" @default.
- Q91392717 P921 Q154874 @default.
- Q91392717 P921 Q4007171 @default.
- Q91392717 P921 Q42824440 @default.
- Q91392717 P921 Q738292 @default.